article thumbnail

Bayer triples sales forecast for prostate cancer drug Nubeqa

pharmaphorum

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The post Bayer triples sales forecast for prostate cancer drug Nubeqa appeared first on.

Sales 98
article thumbnail

Pharma websites need disruption

World of DTC Marketing

We all know that Wall Street and sales come well before patients. Just look at any pharma product website that is nothing but a sales brochure in a majority of cases. ROI drives pharma companies. In the past, pharma product websites had a huge effect on whether a patient asks for an Rx. Want proof?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease

Pharmaceutical Technology

In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence. The firm is also entitled to receive up to $410m for future development and regulatory and commercial milestones, provided these are attained within the timeline of the deal.

article thumbnail

Bayer sells testosterone drug rights to Grünenthal for €500m

pharmaphorum

Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales of €117 million last year.

Drugs 86
article thumbnail

Product launch metrics are changing in pharma

World of DTC Marketing

Today, colossal budget product launches are not returning the same ROI as before. Product launches are going to need to be micro-targeted to specific audiences. What is the definition of a successful pharma product launch? The pandemic has changed both HCP and patient behaviors.

article thumbnail

Russia’s focus on domestic pharma production could shield it from sanctions’ effects

Pharmaceutical Technology

Thermo Fisher states on its website that “Given the ongoing conflict, we have paused sales and manufacturing operations in Russia and Belarus. Pharmstandard (Moscow, Russia) and Pharmasyntez (Irkutsk Oblast, Russia) own five facilities each in Russia, the most of any pharma company. Roszdravnadzor was founded by Vladimir Putin in 2004.

article thumbnail

Leading freeze-drying systems suppliers for the pharmaceutical industry

Pharmaceutical Technology

They offer security in pharmaceutical manufacturing by fulfilling the security rules such as process control settings and specific requirements for the collection of batch production and control records, based on which the pharma products should be produced.